The disclosure provides methods of treatment for cancer in patients using bispecific anti-IGF-lR, anti-ErbB3 antibodies in combination with one or more therapeutic agents that impede regulatory T-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-receptor antibody that immunospecifically binds human PD-L1.
申请公布号
WO2016196377(A1)
申请公布日期
2016.12.08
申请号
WO2016US34846
申请日期
2016.05.27
申请人
MERRIMACK PHARMACEUTICALS, INC.;ADAMS, Sharlene;FINN, Gregory, J.;LOUIS, Chrystal, U.
